Stoking an anti-liver cancer immune response with cryoablation plus an intratumoral TLR9 agonist and dual checkpoint inhibitors
Abstract The rising incidence of hepatocellular carcinoma (HCC) is partly driven by metabolic dysfunction-associated steatohepatitis (MASH). Recurrence after treatment is high, and advanced disease carries a poor prognosis. The immunosuppressive tumor microenvironment (TME) in HCC limits the efficac...
Збережено в:
| Автори: | , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Springer
2026-02-01
|
| Серія: | Cancer Immunology, Immunotherapy |
| Предмети: | |
| Онлайн доступ: | https://doi.org/10.1007/s00262-025-04286-8 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|